AU2023219773A1 - Interleukin-2 muteins for the treatment of autoimmune diseases - Google Patents

Interleukin-2 muteins for the treatment of autoimmune diseases Download PDF

Info

Publication number
AU2023219773A1
AU2023219773A1 AU2023219773A AU2023219773A AU2023219773A1 AU 2023219773 A1 AU2023219773 A1 AU 2023219773A1 AU 2023219773 A AU2023219773 A AU 2023219773A AU 2023219773 A AU2023219773 A AU 2023219773A AU 2023219773 A1 AU2023219773 A1 AU 2023219773A1
Authority
AU
Australia
Prior art keywords
fold
amino acid
seq
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219773A
Other languages
English (en)
Inventor
Nicole AKRAMOFF
Diane MA
Mohit Mathur
David William Oldach
Asher Schachter
Michaela Schultz
Susan Sloan
William C. TUBBS
Jill YARBROUGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of AU2023219773A1 publication Critical patent/AU2023219773A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2023219773A 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases Pending AU2023219773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
AU2023219773A1 true AU2023219773A1 (en) 2024-08-01

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219773A Pending AU2023219773A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Country Status (10)

Country Link
US (1) US20230390360A1 (https=)
EP (1) EP4475875A1 (https=)
JP (1) JP2025506173A (https=)
KR (1) KR20240148001A (https=)
CN (2) CN119013034A (https=)
AU (1) AU2023219773A1 (https=)
CA (1) CA3243493A1 (https=)
MX (1) MX2024009868A (https=)
TW (1) TW202400218A (https=)
WO (1) WO2023154870A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
CN120346304A (zh) 2025-07-22
KR20240148001A (ko) 2024-10-10
US20230390360A1 (en) 2023-12-07
WO2023154870A1 (en) 2023-08-17
MX2024009868A (es) 2024-08-20
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
TW202400218A (zh) 2024-01-01
EP4475875A1 (en) 2024-12-18
CN119013034A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
JP7483857B2 (ja) インターロイキン－２作用物質およびその使用
US20250186539A2 (en) Methods for treating cancer
TWI812918B (zh) IL-7Rαγc結合化合物
TW202142559A (zh) IL-7Rα結合化合物
JP2022507606A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
US20220226442A1 (en) Interleukin-2 agents and uses thereof
US12098178B2 (en) Methods of using interleukin-2 agents
AU2023219773A1 (en) Interleukin-2 muteins for the treatment of autoimmune diseases
HK40124714A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40113125A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
WO2025125652A1 (en) Combination therapy for use in treating cancer